Bot Chart, page-10569

Hey NZT - Nice, and a little encouraging . And indeed biotech IS on fire presently, just as is one of yours that I was watching wistfully when it dropped from 8c to 4c recently, but sadly I didn’t/don’t presently have the funds, and then it went north to 15c, but now around 11c!

Yes, BOT SP has held up well and looks like continuing to do so, as it inches toward the end of the year. My gut feel has always been that BOT Management would likely do some sort of deal following FDA approval (a sell-out preferably) and I am suspecting somebody might be waiting in the wings for the FDA Approval, such being the milestone to meet to initiate such a deal. That said, I can’t imagine BOT selling at a price that would only equate to Sofdra – do you think a potential buyer would put much value in any of the pipeline at this point? I’m sure any deal would be beneficial for shareholders, but just how beneficial is hopefully, the billion dollar question! Do you care to put any sort of guesstimate on where you think the BOT SP could be, following FDA Approval, with any such development as you speculate? Obviously licensing out to somebody wouldn’t be as lucrative as BOT going alone – do you think there is actually anything to be gained by that? They seem to have the marketing & distribution all lined up, so why share really? Your thoughts, if you care to?